<p>4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol- 1 -yl]benzoic acid and pharmaceutically-acceptable salts thereof and a particular crystalline form of the Agent (Form 1); their use in the inhibition of 11 ßHSD1, processes for making them and pharmaceutical compositions comprising them are also described.</p>